MannKind Corp. (NSDQ:MNKD) and One Drop said today that the companies agreed to ink a collaborative deal to add MannKind’s Afrezza inhaled insulin to One Drop’s digital diabetes management platform.
The group plans to evaluate access and cost saving initiatives, customized patient coaching and innovative packaging for a reusable Afrezza inhaler integrated with Bluetooth tech.
Get the full story at our sister site, Drug Delivery Business News.